Table 1.
Core size/hydrodynamic size (nm) | Name | Coating molecule | Model | Dose (mg Fe/kg) | t1/2 | Applications/Investigation | Refs. |
---|---|---|---|---|---|---|---|
4-6/NA1 | USPIO | Dextran | Rats | 15 | 2 h | MRI of spinal cord | [233] |
5/30 | USPIO sinerem | Dextran | Rats | 11.2 | 4 h 30 min | Tumor MRI | [234] |
NA/15 | Fractionated Feridex | Dextran | Rabbits | 4.8 | 15.9 h | MR imaging for atherosclerosis | [235] |
NA/50-80 | Amino-dextran SPIO-micromod | Dextran 20 kDa | Mice | 4 | 5-60 min | Protein absorption analysis | [236] |
3-5/60-80 | Resovist (SHU 555 C, ferucarbotran) | Carboxydextran | Rats | 5.6 | 56 ± 17 min | Imaging of inflammatory bowel disease | [237] |
30/30-70 | Nanoworms | Dextran-PEG2 | Mice | 3 | 16–19 h | Tumor targeting | [67] |
7/NA | NA | Chitosan-chlorotoxin-cy5.5 | Mice | 6.673 | 7–8 h | Cancer targeting and imaging/NIR fluorescence scanner for half-blood life | [24] |
70/NA | NA | Silica + PEG | Rats | 5.7 | 2.5 h | General MRI | [20] |
12/NA and 15/NA | MF66 and OD15 | DMSA4 | Pigs | 0.5 -2 | 15 min | Breast and pancreatic cancer | [238] |
NA/46 and 53 | PDS1 and PDS8 | Dextran-PEG | Mice | 100 | < 1 h | NA | [239] |
NA/29 | NA | EDT5 | Mice | 5 | 6 min | Brain targeting | [232] |
NA/65 | NA | Dextran | Mice | 2 | 150 min | Tumor targeting | [224] |
5-10/194 | SPIO-alginate | Alginate | Rats | 6.1212.23 | 0.25 h0.59 h | MR liver imaging | [134] |
5/15-50 | Ferumoxtran-10 (USPIO, AMI-227) | Dextran | Humans | 2.6 | > 24 h | MRI for detection in lymph nodes | [50] |
5/62-80 | Ferumoxides (SSPIO, AMI-25, SHU 555 A) | Dextran/Carboxydextran | Humans | 1.16 – 11.6 | 3.9 – 8 min | MRI for metastatic lesion detection in liver | [48] |
10/NA35/NA | LUSPIOLSPIO | PEGgylated lipid | Mice | 3.9 | 1.41 h1.01 h | Imaging of oxidation-specific epitopes within the arterial wall | [40] |
5.6/12 | NC100150 | Oxidized starch | Humans | 1, 2 and 5 | 2-3 h6 | Positive-contrastMR angiography | [227] |
7/74.9 | PC SPION | Oleic acid/Encapsulation into phosphatidylo-cholinemicelles | Rats | 0.15 | 10 h | MRI contrast agents/drug delivery | [226] |
26/78 | LS-008 | PMAO7-PEG | Rats | 5 | 4.2 h | MPI tracer | [170] |
3.2/116.2 | NA | PEG-cysteine | Rats | NA | 6.2 h | T1-weighted MR imaging | [88] |
NA/34.1-35.9 | IONP-ICG | Dextran-ICG8-PEG | Mice | 55.8 | 164-197 min | Imaging of macrophages in atherosclerotic plaques | [228] |
NA/50 | MNP-VEGF9@Dox10 | Albumin-PEG-VEGF@Dox | Rats | 5 | 14.6 h | Targeted theranostics of breast cancer | [89] |
9/16 | BFNPs | Fluorescent carbon | Mice | 3.333 | 1.36 h | Photothermal therapy for tumor treatment | [229] |
8-12/30 | RGD10-NGR9-USPIO | Dextran-RGD10-NGR9-peptides | Mice | 25 | 6.2 h | MRI of tumor angiogenesis | [230] |
30-35/94 | MNP@PES-Cy7/2-DG | Poly(4-styrenesulfona-te)-Cyanine7/2-deoxyglucose-polyethylene glycol | Mice | NA (0.075 mg NPs per mouse) | 1.61–2.07 h1116.2–24.56 h12 | Trimodality imaging-guided intracellular photo-magnetic hyperthermia therapy | [240] |
5/140-23013 | Raspberry SPIONs | Oleic acid/GCPQ14 | Mice | 32.5 | 28.3 min | MRI contrast agents | [97] |
14/40 | IONP@PMSEA15 | Oleic acid/PMSEA | Rats | 10 | 5.15 h | Potential delivery agents for therapeutics and diagnostics | [94] |
11/22 | Fe3O4-PEG-5Ab16 | PEG-5Ab | Mice | 10 | 6.96 h | Targeted imaging and enhanced treatment of NHL17 | [241] |
NA/64 | MCP18-PEG10K | PEG 10 kDa | Rats | 2.795.59 | 1.8 min5.2 min | MPI tracers | [80] |
NA/84.1 | MCP-PEG10K2 | PEG 10 kDa (double layer) | Rats | 2.79 | 62.1 min | MPI tracers | [80] |
20.7-22.6/54-76 | RL-1 | PEG-silane | Mice | 6.673 | 6.99 h | MPI tracers | [231] |
10/154 | PEG-starch-IONPS | PEG-starch | Mice | 12 | 2.7 h | Photothermal therapy (PTT) agents | [84] |
13/178 | PTX19@FA20@PEG/PEI21-SPIONs | PTX-FA-PEG/PEI | Rats | NA | 3.41 h | PTX delivery system | [85] |
1NA – not available; 2PEG- polyethylene glycol; 3assuming that each mouse weighed 30 g; 4– dimercaptosuccinid acid, 5– ethylenediaminetriacetate, 6- depending on the dose, 7- poly(maleic anhydride-alt-1-octadecene), 8- indocyanine green, 9- vascular endothelial growth factor, 10- doxorubicin, 11- distribution phase, 12- elimination phase, 13- 5 nm SPIONs clustered into larger raspberry shape, 14- N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan, 15- poly[2-(methylsulfinyl)ethyl acrylate], 16- RTX(rituximab)antibodies, 17- non-Hodgkin lymphoma, 18- magnetic multicore particles, 19- paclitaxel, 20- folic acid, 21- poly(ethyleneimine)